Gus Cairns Editor

Gus joined the editorial team in 2009 and has previously edited HIV Treatment Update and Preventing HIV. He currently focuses on the PrEP in Europe Initiative and on news reporting.

The search for a cure

Novel dual antibody therapy partially controls virulent HIV infection in monkeys off treatment

Transgender people

Studies confirm that hormone levels in trans women are not greatly affected by PrEP, or vice versa

PrEP science

PrEP failures in African programmes are rare, but some are happening in people with good adherence

Injectable & long-acting HIV treatment

Twice-a-year injected drug shows promise for first-line HIV treatment

New & experimental HIV treatments

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

PrEP

PrEP for women in Europe webinar: Part 2

Undetectable viral load & treatment as prevention

HIV infection may become rare in UK gay men by 2030, researchers say

PrEP

PrEP for women in Europe webinar: Part 1

People & personal stories

Forty years a survivor

Resistance

Injectable HIV therapy should only be given after a check for innate resistance, French study suggests

PrEP science

Users of event-driven PrEP take it when needed, Dutch study finds

Retention & linkage to care

Two times a year is better than four: people spend less time off ART if they only visit their clinic every six months, African study shows

PrEP programmes & uptake

Black Africans in UK have limited knowledge of PrEP despite ongoing risk

PrEP programmes & uptake

Improving on a good start: Scotland examines its first four years of PrEP

PrEP programmes & uptake

England's big PrEP implementation trial releases its enrolment data: young people under-represented

Access to healthcare

Testing homeless people during COVID-19 identifies several new HIV cases, especially in Black people

Injectable & long-acting HIV treatment

Injectable HIV therapy would have to cost less than $131 a year to be cost-effective in Africa

Drug interactions & pharmacokinetics

PrEP does not lower hormone levels in young transgender people, but lower PrEP levels seen in some transgender women